Beate Rohde

No ORCID on file · 6 papers in corpus · active 2012-2023

Study types

  • article 5
  • rct 1

Condition tags

  • endometriosis 3
  • mesh:D004715 2
rct 2023
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
European journal of endocrinology ·doi:10.1093/ejendo/lvad063

OBJECTIVE: Aldo-keto reductase 1C3 (AKR1C3) has been postulated to be involved in androgen, progesterone, and estrogen metabolism. Aldo-keto reductase 1C3 inhibition has been proposed for treatment of endometriosis and polycystic ovary synd…

article 2020
Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women
Clinical pharmacology in drug development ·doi:10.1002/cpdd.851

Abstract Vilaprisan is a novel selective progesterone receptor modulator for the long‐term treatment of uterine fibroids and endometriosis. This study investigated the pharmacokinetics, safety, and tolerability of vilaprisan in healthy Chin…

article 2018
Exploratory analysis of molecular pharmacodynamic effects of vilaprisan in the endometrium
·doi:10.1016/j.fertnstert.2018.07.399
article 2018
Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719118776806
article 2016
Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial
Human Reproduction ·doi:10.1093/humrep/dew145

STUDY QUESTION: What are suitable doses of the aromatase inhibitor anastrozole (ATZ) and the progestin levonorgestrel (LNG), when delivered to the systemic circulation by an intravaginal ring (IVR), for further clinical development as a pot…

article 2012
Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women
·doi:10.1016/j.contraception.2012.01.010